Precipitous fall in platelet count with anagrelide: Case report and critique of dosing recommendations

Pharmacotherapy

Volumn 17, Issue 4, 1997, Pages 822-826

  McCune, Jeannine S ^a   Liles, Darla ^a   Lindley, Celeste ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE; BUSULFAN; HYDROXYUREA; INTERFERON; QUINAZOLINE DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; FEMALE; HUMAN; LEUKOPENIA; ORAL DRUG ADMINISTRATION; PLASMAPHERESIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOSIS;

ADULT; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PLATELET AGGREGATION INHIBITORS; QUINAZOLINES; THROMBOCYTOPENIA;

EID: 0030792954     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Frenkel EP. Southwestern Internal Medicine Conference: the clinical spectrum of thrombocytosis and thrombocythemia. Am J Med Sci 1991;301(1):69-80.
2. Silverstein MN, Petitt RM, Solberg LA, et al. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 1992;92:69-72.
3. Spencer CM, Brogden RN. Anagrelide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia. Drugs 1994;47(6):809-22.
4. Gaver RC, Deeb G, Pittman KA, et al. Disposition of anagrelide, an inhibitor of platelet aggregation. Clin Pharmacol Ther 1981;29(3):381-6.
5. Mazur EM, Rosmarin AG, Sohl PA, et al. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood 1992;79(8):1931-7.
6. Andes WA, Noveck RJ, Fleming JS. Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers. Thromb Haemost 1984;52(3):325-8.
7. Silverstein MN, Petitt RM, Solberg LA, et al. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med 1988;318:1292-4.
8. Balduini CL, Bertolino G, Noris P, et al. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. Haematologica 1992;77:40-3.
9. Mazzucconi MG, De Sanctis V, Chistolini A, et al. Therapy with anagrelide in patients affected by essential thrombocythemia: preliminary results. Haematologica 1992;77:315-17.